Opinion
Video
The Potential Benefits of RSV Vaccine Approval for Adults Aged 50-59
Author(s):
As phase 3 data for the RSV vaccine are leading the FDA to consider expanding the age range to include patients aged 50-59, the panel discusses the potential clinical and economic benefits.
EP: 1.Overview of RSV Patient Populations
EP: 2.Complications Associated with RSV Infections
EP: 3.The Economic Burden and Main Drivers of Healthcare Resource Utilization in RSV
EP: 4.RSV: Risk Factors and How It’s Spread
EP: 5.Diagnostic Practices for RSV
EP: 6.Increasing Awareness of RSV Vaccines in At-Risk Patients
EP: 7.Shared Decision-Making Practices in RSV
EP: 8.Financial and Clinical Benefits of RSV Immunization
Now Viewing
EP: 9.The Potential Benefits of RSV Vaccine Approval for Adults Aged 50-59
EP: 10.Addressing Vaccine Fatigue
EP: 11.Identifying Patients Eligible for RSV Vaccine
EP: 12.Current and Potential Obstacles Related to Administering RSV Vaccines
EP: 13.Improving Insurance Coverage for RSV Vaccines
EP: 14.Improving RSV Vaccination Rates and Addressing Misinformation
EP: 15.Key Takeaways on RSV Vaccination
Video content above is prompted by the following questions:
- What is the important phase 3 data for the RSV vaccine that is leading the FDA to consider an expanded age range to 50-59?
- How would RSV vaccine approval for adults aged 50-59 improve the clinical and economic impact of the disease?
- What will the best practices be for identifying patients who are eligible for receiving the RSV vaccine with the potential updated indication?
- How should payers adjust coverage decisions for RSV vaccines in patients aged 50-59 if this expanded indication is approved?
- How should the ACIP/CDC incorporate a potential indication expansion into their recommendations?
- How should the ACIP/CDC incorporate a potential indication expansion into their recommendations?
Related Videos
Related Content
